Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
作者： Nushmia Z. Khokhar , Jessica K. Altman , Leonidas C. Platanias
DOI: 10.1097/CCO.0B013E32834B892D
关键词: Regulator 、 Medicine 、 PI3K/AKT/mTOR pathway 、 Kinase 、 Cell growth 、 Targeted therapy 、 Cancer research
摘要: Purpose of reviewThe mammalian target rapamycin (mTOR) is a key regulator cell growth and survival in cells. mTOR pathways are frequently dysregulated various malignancies, providing targets for new anticancer drugs therapeutic strategies. Here, we summarize the clinical exper
sci-hub.se 参考文章(75)
Arie Zask, Jeroen C Verheijen, David J Richard, Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. Current Opinion in Drug Discovery & Development. ,vol. 13, pp. 428- 440 ,(2010)
Francisco J. Esteva, Hua Guo, Siyuan Zhang, Cesar Santa-Maria, Steven Stone, Jerry S. Lanchbury, Aysegul A. Sahin, Gabriel N. Hortobagyi, Dihua Yu, PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. American Journal of Pathology. ,vol. 177, pp. 1647- 1656 ,(2010) , 10.2353/AJPATH.2010.090885
Sébastien Albert, Maria Serova, Chantal Dreyer, Marie-Paule Sablin, Sandrine Faivre, Eric Raymond, New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opinion on Investigational Drugs. ,vol. 19, pp. 919- 930 ,(2010) , 10.1517/13543784.2010.499121
Joseph Gligorov, David Azria, Moise Namer, David Khayat, Jean-Philippe Spano, None, Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: Focus on clinical trials and perspectives Critical Reviews in Oncology Hematology. ,vol. 64, pp. 115- 128 ,(2007) , 10.1016/J.CRITREVONC.2007.06.010
Alejo Efeyan, David M Sabatini, mTOR and cancer: many loops in one pathway Current Opinion in Cell Biology. ,vol. 22, pp. 169- 176 ,(2010) , 10.1016/J.CEB.2009.10.007
Brian M. Slomovitz, Karen H. Lu, Taren Johnston, Robert L. Coleman, Mark Munsell, Russell R. Broaddus, Cheryl Walker, Lois M. Ramondetta, Thomas W. Burke, David M. Gershenson, Judith Wolf, A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer. ,vol. 116, pp. 5415- 5419 ,(2010) , 10.1002/CNCR.25515
David T. Teachey, Stephan A. Grupp, Valerie I. Brown, Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies British Journal of Haematology. ,vol. 145, pp. 569- 580 ,(2009) , 10.1111/J.1365-2141.2009.07657.X
C A Sparks, D A Guertin, Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene. ,vol. 29, pp. 3733- 3744 ,(2010) , 10.1038/ONC.2010.139
Christian Récher, Odile Beyne-Rauzy, Cécile Demur, Gaëtan Chicanne, Cédric Dos Santos, Véronique Mansat-De Mas, David Benzaquen, Guy Laurent, Françoise Huguet, Bernard Payrastre, Antileukemic activity of rapamycin in acute myeloid leukemia Blood. ,vol. 105, pp. 2527- 2534 ,(2005) , 10.1182/BLOOD-2004-06-2494
D. A. Guertin, D. M. Sabatini, The Pharmacology of mTOR Inhibition Science Signaling. ,vol. 2, ,(2009) , 10.1126/SCISIGNAL.267PE24